软组织肉瘤靶向治疗进展  

Targeted therapy of soft tissue sarcoma

作　　者：郭俊(综述)[1] 李苏宜(审校)[1] 

机构地区：[1]东南大学附属中大医院临床肿瘤科,南京210009

出　　处：《国际肿瘤学杂志》2008年第7期541-543,共3页Journal of International Oncology

摘　　要：化学治疗晚期软组织肉瘤疗效似已达到平台，靶向药物是进一步提高疗效的关键。尽管第1代靶向治疗药物开发的种类繁多，但仅有少数药物在前瞻性、随机的Ⅲ期临床试验中显示出生存优势。第2代靶向治疗药物多靶点抑制剂可同时阻断肿瘤多个信号传导，临床试验的初步结果表明，不良反应可以耐受，效果较好，治疗软组织肉瘤已显示出较好的应用前景。The results of chemotherapy in the treatment of soft tissue sarcoma seem to have reached a plateau. Targeted therapy is the key to improve curative efficacy. Although there are many kinds of targeted therapy drugs of the first generation, only several targeted drugs that target angiogenesis and the epidermal growth factor receptor have showed survival benefits in prospective, randomized, phase Ⅲ clinical trials. Recent data suggest that multitargeted inhibitors might have greater activity owing to their ability to simultaneously block several key signaling pathways. Preliminary results of such agents in clinical trials show that they have a well - tolerated toxicity profile, and might have a promising value in the treatment of soft tissue sarcoma.

关 键 词：软组织肿瘤 抗肿瘤药 药物疗法 

分 类 号：R738.6[医药卫生—肿瘤]